Antitumor Effect of the KRAS G12C Inhibitor Sotorasib combined with Radiotherapy and Carboplatin/Cisplatin in human Lung Carcinoma Cell Lines

被引：0
|
作者：
Maltzahn, Christin [1 ]
Patties, Ina [1 ]
Kortmann, Rolf-Dieter [1 ]
Seidel, Clemens [1 ]
Glasow, Annegret [1 ]
机构：
[1] Univ Leipzig, Klin & Poliklin Strahlentherapie, Leipzig, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2023年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P10-1
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [31] The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma
    Li, Jing Jing
    Wu, Xiao Juan
    Farzin, Mahtab
    Bray, Victoria
    Williamson, Jonathan
    Pal, Abhiji
    Yip, Po Yee
    Hagelamin, Abeer
    Ding, Pei
    Nindra, Udit
    Vinod, Shalini
    French, Bruce
    Chua, Wei
    Gupta, Ruta
    Cooper, Wendy A.
    Wang, Bin
    Lee, C. Soon
    PATHOLOGY, 2024, 56 (06) : 786 - 794
  • [32] Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor sotorasib in lung cancer
    Yagami, Yuri
    Sato, Takashi
    Yamamoto, Hiroki
    Shirasawa, Masayuki
    Nakahara, Yoshiro
    Hideo, Watanabe
    Katsuhiko, Naoki
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
    Schmidt, Jonas Frederik
    Entz, Dominik
    Brasch, Frank
    Goerner, Martin
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 1019 - 1024
  • [34] Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer
    Chopra, D.
    Waterhouse, D. M.
    Sylvester, B.
    Jamotte, A.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S648
  • [35] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [36] GTPase KRAS (G12C mutant) inhibitor Treatment of non-small cell lung cancer Treatment of colorectal cancer
    Shao, Shi-yun
    Rong, Wen-qing
    Talukder, Salehikram
    Jia, Ru
    Chen, Zhe-Sheng
    DRUGS OF THE FUTURE, 2022, 47 (11) : 783 - 795
  • [37] Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
    Johnson, M. L.
    de langen, A. J.
    Waterhouse, D. M.
    Mazieres, J.
    Dingemans, A-M. C.
    Mountzios, G.
    Pless, M.
    Wolf, J.
    Schuler, M.
    Lena, H.
    Skoulidis, F.
    Okamoto, I.
    Kim, S-W.
    Linardou, H.
    Novello, S.
    Chen, Y.
    Solomon, B.
    Obiozor, C.
    Wang, Y.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1417 - S1418
  • [38] Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer
    Adachi, Yuta
    Ito, Kentaro
    Hayashi, Yuko
    Kimura, Ryo
    Tan, Tuan Zea
    Yamaguchi, Rui
    Ebi, Hiromichi
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5962 - 5973
  • [39] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [40] Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
    Manabe, Tadashi
    Bivona, Trever G.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (04):
12345